1. Mavacamten demonstrated substantial enhancement in alleviating valsalva left ventricular outflow tract (LVOT) obstruction in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) compared to placebo, with favorable tolerability. 2. Additionally, all secondary measures of effectiveness, including New York Heart Association (NYHA) functional class, health status, cardiac biomarkers, and cardiac structure, displayed improvements. Evidence Rating